| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/06/2013 | CN102949343A Method for increasing fat-soluble drug loading capacity in liposome |
| 03/06/2013 | CN102949337A Gemcitabine hydrochloride injection and preparation method thereof |
| 03/06/2013 | CN102949333A 16-dehydropregnenolone pessary for treating cervical cancer and preparation method thereof |
| 03/06/2013 | CN102949307A LTBP-4 generation accelerant |
| 03/06/2013 | CN102948758A Method for extracting buckwheat flavone from buckwheat bran |
| 03/06/2013 | CN102671140B Anticancer traditional Chinese medicine combination oral liquid, preparation method and detection method thereof |
| 03/06/2013 | CN102657823B Traditional Chinese medicine composition with anticancer effect and preparation method and detection method thereof |
| 03/06/2013 | CN102579355B Mitoxantrone nano calcium hydrophosphate preparation and preparation method thereof |
| 03/06/2013 | CN102579347B Thymalfasin liposome preparation for injecting |
| 03/06/2013 | CN102309763B Medicinal composition and preparation method thereof |
| 03/06/2013 | CN102302499B Capsule preparation containing tegafur, gimeracil and potassium oxonate |
| 03/06/2013 | CN102274521B Graphene oxide-based target gene vector material and preparation and use thereof |
| 03/06/2013 | CN102241790B Amphipathic chitosan derivative and preparation method and application thereof |
| 03/06/2013 | CN102238959B Composition comprising bacillus calmette guerin polysaccharides and bacillus calmette guerin nucleic acids and use of preparing medicament thereof |
| 03/06/2013 | CN102232962B Composition containing astragaloside active components as well as preparation method and application thereof |
| 03/06/2013 | CN102232945B Antrodia camphorata cyclohexenone compound for suppressing growth of bladder cancer tumor cells |
| 03/06/2013 | CN102218058B Application of sparstolenin B as TLR2 (Toll-like receptor 2)/TLR4 (Toll-like receptor 4) antagonist in pharmacy |
| 03/06/2013 | CN102199184B Hederasaponin derivative, preparation method of salts thereof and application thereof to resisting tumor |
| 03/06/2013 | CN102112141B Composition useful for prevention or reduction of progression of prostate cancer |
| 03/06/2013 | CN102094042B Recombinant vector of ZNF300 gene and application thereof |
| 03/06/2013 | CN102068447B Application of triterpenoid saponin compound in preparation of medicaments for treating autoimmune diseases |
| 03/06/2013 | CN102030813B Preparation method and application of yellow ginger zingiberensis saponin having high-efficiency anti-cancer activity |
| 03/06/2013 | CN101983968B Preparation method of sepia oligopeptide by enzymatic hydrolysis |
| 03/06/2013 | CN101863960B Preparation method of cetrorelix |
| 03/06/2013 | CN101820758B Novel forms of cddo methyl ester |
| 03/06/2013 | CN101817833B DPP-IV inhibitor |
| 03/06/2013 | CN101812127B Microtubule-associated protein and coding genes and application thereof |
| 03/06/2013 | CN101772353B Oxidized avidin with high residency time in the treated tissues |
| 03/06/2013 | CN101759544B Novel chalcone compound and preparation method and application thereof |
| 03/06/2013 | CN101757039B Bionic enzymolysis products of geckos and application thereof |
| 03/06/2013 | CN101658676B Novel cell targeted medicine delivery carrier, medicine composition containing same and method for delivering medicine by same |
| 03/06/2013 | CN101643451B Peroxisome proliferator-activated receptor subtype delta agonist compound and preparation method thereof |
| 03/06/2013 | CN101573363B Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 03/06/2013 | CN101442994B Methods and compositions for treating hematological malignancies |
| 03/06/2013 | CN101190329B Medicinal composition for regrouping human P43 protein and its application in medication |
| 03/06/2013 | CN101119988B Chemical compouns |
| 03/06/2013 | CN101010101B Composition comprising protein material and non-oxidizable fatty acid entities |
| 03/05/2013 | US8389747 for treatment of insulin-like growth factor-1 receptor (IGF-1R) dependent diseases, such as cancer, psoriasis, atherosclerosis and acromegaly; preferred compound is picropodophyllin |
| 03/05/2013 | US8389721 Solubilized topoisomerase poisons |
| 03/05/2013 | US8389563 C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers |
| 03/05/2013 | US8389537 Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide |
| 03/05/2013 | US8389499 Cyclodextrin-based polymers for therapeutics delivery |
| 03/05/2013 | US8389497 Using of alkylphosphocholines for the manufacture of a drug product for the therapy of benign and malignant oncoses |
| 03/05/2013 | US8389491 Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same |
| 03/05/2013 | US8389484 Methods for targeting RNA molecules |
| 03/05/2013 | US8389043 Preparation for restenosis prevention |
| 03/05/2013 | US8389006 Pharmaceutical compositions of adsorbates of amorphous drug |
| 03/05/2013 | US8388975 Cancer antigen peptides derived from WT1 |
| 03/05/2013 | US8388971 Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses |
| 03/05/2013 | US8388966 Combination treatment of pancreatic cancer |
| 03/05/2013 | US8388961 Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| 03/05/2013 | US8388957 Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| 03/05/2013 | CA2595610C Antibodies directed to angiopoietin-2 and uses thereof |
| 02/28/2013 | WO2013028866A1 Therapeutic compounds and methods |
| 02/28/2013 | WO2013028832A2 Inhibitors of nedd8-activating enzyme |
| 02/28/2013 | WO2013028664A1 Psma imaging agents |
| 02/28/2013 | WO2013028543A1 Bax agonist, compositions, and methods related thereto |
| 02/28/2013 | WO2013028541A1 Vegf-binding protein for blockade of angiogenesis |
| 02/28/2013 | WO2013028505A1 Combination cancer therapy of hsp90 inhibitor with antimetabolite |
| 02/28/2013 | WO2013028442A1 Anti-tie2 antibodies uses thereof |
| 02/28/2013 | WO2013028334A2 Use of small molecules in methods for purification of biomolecules |
| 02/28/2013 | WO2013028231A1 Anti-ox40 antibodies and methods of using the same |
| 02/28/2013 | WO2013028137A1 A protein involved in detection of cancer metastasis and a treatment thereof |
| 02/28/2013 | WO2013028051A1 Composition comprising sandoricum koetjape extracts and uses thereof |
| 02/28/2013 | WO2013027988A2 Recombinant adenovirus comprising trans-splicing ribozyme and cancer-treating gene, and use thereof |
| 02/28/2013 | WO2013027802A1 Novel anti-ddr1 antibody having anti-tumor activity |
| 02/28/2013 | WO2013027680A1 Drug for preventing exacerbation of malignant tumor, comprising combination of natriuretic peptide receptor gc-a agonist and gc-b agonist |
| 02/28/2013 | WO2013027658A1 Cartilage/bone destruction suppressor |
| 02/28/2013 | WO2013027168A1 Novel heterocyclic compounds as bromodomain inhibitors |
| 02/28/2013 | WO2013026942A1 Tubulin binding agents |
| 02/28/2013 | WO2013026914A1 Serine/threonine pak1 inhibitors |
| 02/28/2013 | WO2013026874A1 Cdk9 inhibitors in the treatment of midline carcinoma |
| 02/28/2013 | WO2013026839A1 Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| 02/28/2013 | WO2013026837A1 Bispecific t cell activating antigen binding molecules |
| 02/28/2013 | WO2013026835A1 Fc-free antibodies comprising two fab fragments and methods of use |
| 02/28/2013 | WO2013026833A1 Bispecific t cell activating antigen binding molecules |
| 02/28/2013 | WO2013026832A1 Anti-mcsp antibodies |
| 02/28/2013 | WO2013026831A1 Bispecific antigen binding molecules |
| 02/28/2013 | WO2013026516A1 Bicyclic heteroaromatic compounds |
| 02/28/2013 | WO2013026454A1 Treatment of clinical conditions with anthracyclines |
| 02/28/2013 | WO2013026429A1 Novel use of a yt cell line for the therapy of malignant diseases and viral infections and for producing interferon gamma |
| 02/28/2013 | WO2013026383A1 Tetrandrine derivatives with substituted 5-carbon, preparation method and use thereof |
| 02/28/2013 | WO2013026373A1 Use of berbamine for treating chronic myeloid leukemia |
| 02/28/2013 | WO2013026334A1 Cell dna synthesis prevention and cell proliferation inhibition polypeptide and use thereof |
| 02/28/2013 | WO2013026268A1 Tumor chemotherapeutic drug formulation and preparation method thereof |
| 02/28/2013 | WO2013026157A1 Anti-cancer peptides and uses thereof |
| 02/28/2013 | WO2013026113A1 Use of fucosylated chondroitin sulfate, pharmaceutical composition and method for prevention and/or treatment of cancer metastasis |
| 02/28/2013 | WO2013026099A1 Fn14 binding proteins and uses thereof |
| 02/28/2013 | WO2013003112A9 Methods and compositions for treatment of cancer and autoimmune disease |
| 02/28/2013 | WO2012177935A8 Compositions and methods for the treatment of cancer |
| 02/28/2013 | WO2012166705A3 Supramolecular nanofibers and hydrogels based on amino acid-nucleobase-glycoside conjugates |
| 02/28/2013 | WO2012159006A3 Polypeptides and vectors for targeting her2/neu expressing cells and uses thereof |
| 02/28/2013 | WO2012158960A3 Melanocortin 1 receptor ligands and methods of use |
| 02/28/2013 | WO2012138988A3 Organometallic anti-cancer complexes |
| 02/28/2013 | WO2012128998A3 Method for delivering gene and cell therapy to a tumor or targeted site using an implanted metronomic biofeedback pump |
| 02/28/2013 | WO2007025388A9 Anti-apoptotic protein antibodies |
| 02/28/2013 | US20130053449 Method for inhibiting histone gene transcription and expression |
| 02/28/2013 | US20130053446 Pharmaceutical preparations having individualized dosage and structure |
| 02/28/2013 | US20130053436 Compounds, compositions and methods |
| 02/28/2013 | US20130053434 Irreversible inhibitors useful for the treatment of kinase-related pathologies |